[Form 4] Edwards Lifesciences Corp Insider Trading Activity
Edwards Lifesciences (EW) 鈥� Form 4 insider transaction
Company Vice President, JAPAC, Daniel J. Lippis reported the sale of 4,114 EW common shares on 07/28/2025. Trades were executed in multiple lots at prices between $79.45 and $79.47, producing a weighted-average sale price of $79.4605. Following the sale, Lippis鈥� direct beneficial ownership stands at 22,001.9103 shares. No derivative transactions were reported and no other changes in ownership were disclosed.
The filing is limited to this single transaction; it does not detail additional holdings or option grants. Form 4 timing complies with SEC rules, indicating the trade likely settled on, or shortly before, the reported date.
Edwards Lifesciences (EW) 鈥� Transazione interna Form 4
Il Vice Presidente dell'azienda per JAPAC, Daniel J. Lippis, ha comunicato la vendita di 4.114 azioni ordinarie EW il 28/07/2025. Le operazioni sono state eseguite in pi霉 tranche a prezzi compresi tra $79,45 e $79,47, con un prezzo medio ponderato di $79,4605. Dopo la vendita, la detenzione diretta di Lippis ammonta a 22.001,9103 azioni. Non sono state segnalate transazioni su strumenti derivati n茅 altri cambiamenti nella propriet脿.
La comunicazione riguarda esclusivamente questa singola operazione; non fornisce dettagli su ulteriori partecipazioni o assegnazioni di opzioni. Il tempismo del Form 4 rispetta le norme SEC, suggerendo che la transazione si 猫 probabilmente conclusa nella data indicata o poco prima.
Edwards Lifesciences (EW) 鈥� Transacci贸n interna Formulario 4
El Vicepresidente de la compa帽铆a para JAPAC, Daniel J. Lippis, report贸 la venta de 4,114 acciones comunes de EW el 28/07/2025. Las operaciones se realizaron en m煤ltiples lotes a precios entre $79.45 y $79.47, con un precio promedio ponderado de $79.4605. Tras la venta, la propiedad directa beneficiosa de Lippis es de 22,001.9103 acciones. No se reportaron transacciones con derivados ni otros cambios en la propiedad.
El informe se limita a esta 煤nica transacci贸n; no detalla otras participaciones o concesiones de opciones. El momento del Formulario 4 cumple con las normas de la SEC, indicando que la operaci贸n probablemente se liquid贸 en la fecha reportada o poco antes.
Edwards Lifesciences (EW) 鈥� Form 4 雮措秬鞛� 瓯半灅
須岇偓 JAPAC 攵�靷灔 Daniel J. Lippis臧� 2025雲� 7鞗� 28鞚检棎 EW 氤错喌欤� 4,114欤茧ゼ 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 瓯半灅電� 鞐煬 瓯挫溂搿� 雮橂垊鞏� $79.45鞐愳劀 $79.47 靷澊鞚� 臧�瓴╈棎 觳搓舶霅橃棃鞙茧┌, 臧�欷戫弶攴� 毵る弰 臧�瓴╈潃 $79.4605鞓�鞀惦媹雼�. 毵る弰 頉� Lippis鞚� 歆侅爲 鞁れ 靻岇湢 欤检嫕 靾橂姅 22,001.9103欤�鞛呺媹雼�. 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞙茧┌, 靻岇湢甓� 氤�瓴诫弰 鞐嗢棃鞀惦媹雼�.
鞚措矆 氤搓碃電� 雼澕 瓯半灅鞐� 頃滌爼霅橂┌, 於旉皜 氤挫湢 欤检嫕鞚措倶 鞓奠厴 攵�鞐� 雮挫棴鞚� 韽暔頃橃 鞎婌姷雼堧嫟. Form 4 鞝滌稖 鞁滌爯鞚� SEC 攴滌爼鞚� 欷�靾橅晿鞐�, 瓯半灅臧� 氤搓碃霅� 雮犾 霕愲姅 攴� 歆侅爠鞐� 觳搓舶霅橃棃鞚� 臧�電レ劚鞚� 雴掛姷雼堧嫟.
Edwards Lifesciences (EW) 鈥� Transaction d鈥檌niti茅 Formulaire 4
Le vice-pr茅sident de la soci茅t茅 pour la r茅gion JAPAC, Daniel J. Lippis, a d茅clar茅 la vente de 4 114 actions ordinaires EW le 28/07/2025. Les transactions ont 茅t茅 r茅alis茅es en plusieurs lots 脿 des prix compris entre 79,45 $ et 79,47 $, avec un prix de vente moyen pond茅r茅 de 79,4605 $. Apr猫s la vente, la d茅tention directe effective de Lippis s鈥櫭﹍猫ve 脿 22 001,9103 actions. Aucune transaction sur d茅riv茅s ni autre changement de propri茅t茅 n鈥檃 茅t茅 signal茅.
Le d茅p么t se limite 脿 cette seule op茅ration ; il ne d茅taille pas d鈥檃utres participations ou attributions d鈥檕ptions. Le calendrier du formulaire 4 est conforme aux r猫gles de la SEC, indiquant que la transaction a probablement 茅t茅 r茅gl茅e 脿 la date indiqu茅e ou peu avant.
Edwards Lifesciences (EW) 鈥� Insider-Transaktion Form 4
Der Vizepr盲sident des Unternehmens f眉r JAPAC, Daniel J. Lippis, meldete den Verkauf von 4.114 EW-Stammaktien am 28.07.2025. Die Trades wurden in mehreren Tranchen zu Preisen zwischen
Die Meldung beschr盲nkt sich auf diese einzelne Transaktion; es werden keine weiteren Beteiligungen oder Optionszuteilungen angegeben. Das Timing des Form 4 entspricht den SEC-Vorschriften, was darauf hinweist, dass der Handel wahrscheinlich am oder kurz vor dem gemeldeten Datum abgewickelt wurde.
- Timely compliance with SEC Section 16(a) reporting requirements, indicating strong governance processes.
- Officer retains 22,001.9103 shares, preserving equity alignment with shareholders.
- Sale of 4,114 shares (~15% of the officer's prior direct holdings) marginally reduces insider ownership and may be viewed as a slight negative signal.
Insights
TL;DR: Small insider sale; negligible impact on EW valuation.
The transaction represents roughly $0.33 million in proceeds and leaves the officer with about 22 k shares (鈮�$1.75 million at the sale price). Given EW鈥檚 >$45 billion market cap, the sale is immaterial to the share float and earnings outlook. Insider sales can signal caution, but the amount (鈮�0.004% of shares outstanding) and continuing ownership suggest routine diversification rather than a strategic statement. No derivative exercises or option expirations accompany the sale, further indicating a standard open-market disposition.
TL;DR: Routine Form 4, governance compliance intact.
Timely filing within the two-business-day window demonstrates adherence to Section 16(a). The absence of complex instruments or indirect holdings lowers governance risk. While any insider sale can draw scrutiny, the officer retains a meaningful equity stake, maintaining alignment with shareholder interests. No red flags such as clustered executive sales, large percentage disposals, or Form 144 intentions are evident.
Edwards Lifesciences (EW) 鈥� Transazione interna Form 4
Il Vice Presidente dell'azienda per JAPAC, Daniel J. Lippis, ha comunicato la vendita di 4.114 azioni ordinarie EW il 28/07/2025. Le operazioni sono state eseguite in pi霉 tranche a prezzi compresi tra $79,45 e $79,47, con un prezzo medio ponderato di $79,4605. Dopo la vendita, la detenzione diretta di Lippis ammonta a 22.001,9103 azioni. Non sono state segnalate transazioni su strumenti derivati n茅 altri cambiamenti nella propriet脿.
La comunicazione riguarda esclusivamente questa singola operazione; non fornisce dettagli su ulteriori partecipazioni o assegnazioni di opzioni. Il tempismo del Form 4 rispetta le norme SEC, suggerendo che la transazione si 猫 probabilmente conclusa nella data indicata o poco prima.
Edwards Lifesciences (EW) 鈥� Transacci贸n interna Formulario 4
El Vicepresidente de la compa帽铆a para JAPAC, Daniel J. Lippis, report贸 la venta de 4,114 acciones comunes de EW el 28/07/2025. Las operaciones se realizaron en m煤ltiples lotes a precios entre $79.45 y $79.47, con un precio promedio ponderado de $79.4605. Tras la venta, la propiedad directa beneficiosa de Lippis es de 22,001.9103 acciones. No se reportaron transacciones con derivados ni otros cambios en la propiedad.
El informe se limita a esta 煤nica transacci贸n; no detalla otras participaciones o concesiones de opciones. El momento del Formulario 4 cumple con las normas de la SEC, indicando que la operaci贸n probablemente se liquid贸 en la fecha reportada o poco antes.
Edwards Lifesciences (EW) 鈥� Form 4 雮措秬鞛� 瓯半灅
須岇偓 JAPAC 攵�靷灔 Daniel J. Lippis臧� 2025雲� 7鞗� 28鞚检棎 EW 氤错喌欤� 4,114欤茧ゼ 毵る弰頄堧嫟瓿� 氤搓碃頄堨姷雼堧嫟. 瓯半灅電� 鞐煬 瓯挫溂搿� 雮橂垊鞏� $79.45鞐愳劀 $79.47 靷澊鞚� 臧�瓴╈棎 觳搓舶霅橃棃鞙茧┌, 臧�欷戫弶攴� 毵る弰 臧�瓴╈潃 $79.4605鞓�鞀惦媹雼�. 毵る弰 頉� Lippis鞚� 歆侅爲 鞁れ 靻岇湢 欤检嫕 靾橂姅 22,001.9103欤�鞛呺媹雼�. 韺岇儩靸來拡 瓯半灅電� 氤搓碃霅橃 鞎婌晿鞙茧┌, 靻岇湢甓� 氤�瓴诫弰 鞐嗢棃鞀惦媹雼�.
鞚措矆 氤搓碃電� 雼澕 瓯半灅鞐� 頃滌爼霅橂┌, 於旉皜 氤挫湢 欤检嫕鞚措倶 鞓奠厴 攵�鞐� 雮挫棴鞚� 韽暔頃橃 鞎婌姷雼堧嫟. Form 4 鞝滌稖 鞁滌爯鞚� SEC 攴滌爼鞚� 欷�靾橅晿鞐�, 瓯半灅臧� 氤搓碃霅� 雮犾 霕愲姅 攴� 歆侅爠鞐� 觳搓舶霅橃棃鞚� 臧�電レ劚鞚� 雴掛姷雼堧嫟.
Edwards Lifesciences (EW) 鈥� Transaction d鈥檌niti茅 Formulaire 4
Le vice-pr茅sident de la soci茅t茅 pour la r茅gion JAPAC, Daniel J. Lippis, a d茅clar茅 la vente de 4 114 actions ordinaires EW le 28/07/2025. Les transactions ont 茅t茅 r茅alis茅es en plusieurs lots 脿 des prix compris entre 79,45 $ et 79,47 $, avec un prix de vente moyen pond茅r茅 de 79,4605 $. Apr猫s la vente, la d茅tention directe effective de Lippis s鈥櫭﹍猫ve 脿 22 001,9103 actions. Aucune transaction sur d茅riv茅s ni autre changement de propri茅t茅 n鈥檃 茅t茅 signal茅.
Le d茅p么t se limite 脿 cette seule op茅ration ; il ne d茅taille pas d鈥檃utres participations ou attributions d鈥檕ptions. Le calendrier du formulaire 4 est conforme aux r猫gles de la SEC, indiquant que la transaction a probablement 茅t茅 r茅gl茅e 脿 la date indiqu茅e ou peu avant.
Edwards Lifesciences (EW) 鈥� Insider-Transaktion Form 4
Der Vizepr盲sident des Unternehmens f眉r JAPAC, Daniel J. Lippis, meldete den Verkauf von 4.114 EW-Stammaktien am 28.07.2025. Die Trades wurden in mehreren Tranchen zu Preisen zwischen
Die Meldung beschr盲nkt sich auf diese einzelne Transaktion; es werden keine weiteren Beteiligungen oder Optionszuteilungen angegeben. Das Timing des Form 4 entspricht den SEC-Vorschriften, was darauf hinweist, dass der Handel wahrscheinlich am oder kurz vor dem gemeldeten Datum abgewickelt wurde.
FAQ
How many Edwards Lifesciences (EW) shares did Daniel J. Lippis sell?
What price did the EW shares sell for?
How many EW shares does the insider still own after the sale?
Were any derivative securities involved in this Form 4?
Does this filing suggest a change in Edwards Lifesciences鈥� outlook?
